History Study News Today

REDWOOD CITY, Calif., April 30, 2024 -- Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the...

Latest clinical data on BB-301 treatment for OPMD. Positive results in swallowing improvement. Benitec Biopharma announces interim findings and $40 million PIPE financing.

INDIANAPOLIS - Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company , today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated...

-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women ---- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a cli...

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support...

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...

The FDA has approved Sohonos™ (palovarotene) for patients with fibrodysplasia ossificans progressiva.

Blood disorders known as myelodysplastic syndromes/neoplasms (MDS) are difficult to diagnose – and are commonly misdiagnosed – putting patients at increased risk for treatment mistakes and other potentially harmful consequences, according to researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations.

Patients with myelodysplastic syndrome should seek an expert opinion on their disease to ensure an accurate diagnosis and proper treatment plan.

Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF...